Notably, PDX 305R-Cx, which has BRCA2 copy number loss, had reduced tumor volume with talazoparib treatment alone compared to vehicle control, consistent with occasional responses to PARP inhibitors in patients with monoallelic BRCA2 loss (Fig. 5c–e)34. This evidence concerns the gene PARP1 and neoplasm.